SUMMARY During 30 years of follow-up, there were 183 sadden deaths hi men and 77 hi women ages 35 to 94 years who participated hi the Framingham Study. Risk of sudden death was increased threefold in hypertensive persons but only if there was no previously diagnosed coronary heart disease. Men receiving antihypertensive treatment had more than twice the risk of sudden death compared with those who were untreated, whether or not they had prior manifestations of coronary heart disease. More than twice as many men who died suddenly were receiving antihypertensive therapy compared with those hi the population at risk of the same age. In those with overt coronary heart disease, 34% of those dying suddenly were on antihypertensive treatment compared with 18% of those of the same age in the general population. Multivariate analysis taking into account the level of blood pressure, electrocardiographic abnormalities, and previously diagnosed coronary heart disease and cardiac failure, all of which are predisposing factors for sudden death, indicated a persistent increased risk of sudden death hi association with antihypertensive treatment. Tests of interaction indicate that the excess sudden death risk was not confined to those with electrocardiographic abnormalities. In women, it may be associated with diabetes. These data suggest that some feature of antihypertensive treatment as practiced hi the general population may contribute to sudden death incidence in an ill-defined subgroup of hypertensive persons. factor for atherosclerosis, accelerating lipidinduced atherogenesis. Indeed, hypertension may play an essential role since atherosclerosis seldom occurs in low pressure segments of the circulation, such as in the pulmonary arteries or veins.
H
YPERTENSION is a powerful predisposing factor for atherosclerosis, accelerating lipidinduced atherogenesis. Indeed, hypertension may play an essential role since atherosclerosis seldom occurs in low pressure segments of the circulation, such as in the pulmonary arteries or veins. 1 Controlled trials have indicated the efficacy of antihypertensive therapy in prolonging life and delaying onset of strokes, cardiac failure, and renal insufficiency. Animal experiments have demonstrated effectiveness of blood pressure reduction in slowing lipid-induced atherogenesis. 6 However, the efficacy of antihyperten-sive therapy in avoiding coronary heart disease (CHD) has been less well demonstrated. 78 The purpose of this report is to examine the role of hypertension in the development of sudden death in the Framingham Study cohort and the impact of antihypertensive treatment on sudden death incidence.
Subjects and Methods
The Framingham Study cohort was originally composed of 5209 men and women aged 30 to 62 years on entry into the study between 1948 and 1952. 9 This report is based on information derived from subjects aged 35 to 94 years at the biennial examinations. New CHD events were monitored at biennial intervals by reexamination, daily monitoring of hospitalizations, information from personal physicians, medical examiner's reports, and death certificates. 10 ' " The circumstances of each death were carefuly determined from hospital records, medical examiner's reports, and interviews with spouses and personal physicians.
Atherogenic traits and life-styles possibly predisposing to CHD were recorded biennially. These in-H-46 ANTfflYPERTENSIVE DRUG EFFECTS SUPPL n HYPERTENSION, VOL 11, No 3, MARCH 1988 eluded cigarette habit, serum lipids, blood glucose, and blood pressure. 9 The methodology, sampling procedure, laboratory methods, criteria for disease end points, and completeness of follow-up have been published elsewhere. The assignment of coronary heart disease as a cause of sudden death is inferential. Coronary cause is assumed when other possible causes such as ruptured or dissecting aneurysm, pulmonary embolism, and trauma are excluded clinically or by means of postmortem examination. Under these circumstances, death within minutes in persons not otherwise ill with a potentially lethal illness was designated as a coronary sudden death.
10 " Subjects aged 35 to 94 years were classified according to level of suspected cardiovascular risk factors, CHD or congestive heart failure status, electrocardiographic (ECG) abnormality, and antihypertensive treatment status at each biennial examination by age and sex. To examine the risk factors related to occurrence of sudden death, person-bienniums were used to form 2-year age-adjusted incidence rates. Subjects at risk were followed for 2 years for occurrence of sudden death in relation to age, sex, and antihypertensive treatment status with and without prior CHD. Tests of significance and estimates of risk ratios for occurrence of sudden death in relation to blood pressure and antecedent antihypertensive treatment were based on logistic regression models. 12 ' l3 Risk factors considered in addition to blood pressure and antihypertensive treatment for assessment of the net effect of treatment included cholesterol, cigarette habit, glucose intolerance, relative weight, hematocrit, and vital capacity. Risk factors and age were redefined for each subject at the beginning of each biennium.
The criteria for hypertension are based on two systolic and diastolic blood pressure measurements taken at each biennial examination. A participant was considered to have definite hypertension if both systolic pressures were equal to or exceeded 160 mm Hg or if both diastolic blood pressures were 95 mm Hg or greater or if one systolic and one diastolic pressure exceeded these limits. Participants were classified as having borderline hypertension if they had either one systolic blood pressure between 140 and 159 mm Hg or one diastolic blood pressure between 90 and 94 mm Hg but not meeting the criteria for definite hypertension previously stated. In the early portion of the study, diuretics and reserpine were the predominant drugs used, and /3-blockers were among the drugs used for treatment in the last 10 years of the study.
Results

Sodden Death Incidence
During 30 years of biennial surveillance of the cohort of 5204 subjects, aged 35 to 94 years, there were 183 sudden coronary deaths in men and 77 in women. There were 142 sudden deaths without other evidence of overt CHD and 118 with prior evidence of CHD. This constitutes a biennial overall incidence of 6.3 per 1000 for men and 2.0 per 1000 women. Women lagged behind men in incidence by approximately 20 years. Incidence increased sharply with age in both sexes, with the gap in incidence between the sexes closing with advancing age. Incidence rates in those with prior CHD were six to eight times that of those free of CHD ( Table 1 ). The age trend in those with CHD was markedly blunted, particularly in men. However, rates were lower in women with prior CHD.
Hypertension
Risk of all initial clinical manifestations of coronary heart disease, including sudden death, increased in relation to the severity of hypertension (Table 2) . At all levels of hypertension, women maintained their advantage over men with respect to development of clinical coronary events, including sudden death. In those free of prior CHD, risk of sudden death in both sexes was significantly related to the level of both systolic and diastolic pressures (Table 3 ). There was no evidence of a closer relationship to diastolic than to systolic pressure, nor was there evidence of any critical value of pressure. Treatment for hypertension is not taken into account in Tables 2 and 3 . Hence, treated subjects are classified according to their blood pressure readings.
In sharp contrast to those without prior overt CHD, risk of sudden death in those with prior CHD was neither significantly nor strongly related to hypertensive status (Table 4) . At all levels of blood pressure, subjects with prior CHD were at a substantially increased risk of sudden death, including normotensive participants, and the risk ratios for sudden death were not significantly greater in hypertensive than in normotensive subjects. Only in those without prior CHD was hypertension a significant contributor to the incidence of sudden death.
Antihypertensive Treatment
In the early years of the Framingham Study, there was little treatment for hypertension. However, by the third decade, 68% of male hypertensive and 80% of female hypertensive subjects were under treatment. Persons who indicated that they were taking antihypertensive drugs were at approximately twice the risk of sudden death compared with those who were not (Table 5). This is not unexpected since they had higher pressures. What is unexpected is that they exhibited this increased risk even if they had prior CHD (significant for men only). Furthermore, examination of sudden death risk confined to those with hypertension continues to show the same doubling of risk in those receiving antihypertensive therapy (Table 6 ). Table 7 also indicates that the current use of antihypertensive medication was twice as common among those who experienced sudden death, whether or not they had prior CHD.
A multivariate analysis was performed to examine the net effect of antihypertensive treatment, taking into account not only the actual level of blood pressure but all the other cardiovascular risk factors, ECG abnormalities, and cardiac failure as well. This analysis indicates a marginally significant independent contribution of antihypertensive treatment to sudden death incidence in men without prior CHD and a significant effect among men with prior CHD. Because the coeffi- cients for antihypertensive treatment in those with and without prior CHD are similar in magnitude, we combined these two groups in order to increase the likelihood of detecting a significant contribution for antihypertensive treatment (Table 8) . From earlier work, 14 we have noted that generally the risk profiles for sudden death are different for those with and without prior CHD. Therefore, we incorporated all the variables given in Table 9 and then ran a stepwise regression on interactions between CHD status and all measures between age and vital capacity in the list. The significant interactions are indicated in Table 8 . The results of Table 8 indicate that antihypertensive treatment provides a significant independent contribution to the risk of sudden death among men and a marginally significant contribution among women.
Additional analyses were undertaken to exclude possible selection bias by considering the risk profile among treated persons at the exam before treatment. These results confirm those presented in Tables 9 and  10 . Evidently, prior risk factors, blood pressure level, ECG findings, and coronary disease and cardiac failure status, which might have influenced the decision to treat, do not account for the increased sudden death risk observed in those receiving treatment, nor apparently do differences in the intensity of treatment (Table  9) . A significantly greater reduction in pressure was noted in men without prior CHD who later died suddenly, though in women the opposite is indicated. The average length of treatment was quite similar.
Interactions
Because the Multiple Risk Factor Intervention Trial 7 data strongly suggested that in high-risk coronary candidates treated for hypertension and free of clinical CHD drug treatment was associated with higher mortality, including sudden death, in the presence of ECG abnormalities but not in their absence, an analysis was carried out to try to detect such an interaction. A high- HBP = high blood pressure; CHD = coronary heart disease.
risk subgroup of the cohort, based on one or more of hypertension, glucose intolerance, serum cholesterol over 240 mg/dl, and more than 20 cigarettes per day, was defined and placed at risk of sudden death depending on whether the subjects did or did not have ECG abnormalities (Table 10 ). This was done for both those with and without prior CHD. Although those receiving antihypertensive treatment had twice as many ECG abnormalities as those not receiving treatment, there was no indication that the excess mortality was confined to those with ECG abnormality. Regression analyses also do not support a significant interaction between treatment and ECG abnormality. In fact, the most striking adverse, though not significant, effect of antihypertensive treatment was noted in men with prior CHD who had no ECG abnormality (Table 10 ). In those of both sexes who were without ECG abnormality and no prior CHD and who were at high CHD risk, antihypertensive treatment was associated with a significant increased risk of sudden death. Only in men with prior CHD was there a significantly increased risk of sudden death associated with treatment when coexistent ECG abnormality was present. An attempt was undertaken to detect other subgroups that might be at elevated risk of sudden death when treated for high blood pressure. The analyses were performed by incorporating all the variables in Table 9 and performing stepwise regression on interaction terms between antihypertensive treatment status and the other variables in the model. No significant interactions were detected for men. The data for women suggest that in those with prior CHD, antihypertensive treatment strongly predisposes to sudden death if there is coexistent diabetes (Table 11 ). The risk ratio for sudden death in those receiving antihypertensive therapy who had impaired glucose tolerance was 3.8, whereas sudden death risk in those on treatment who were without diabetic tendencies was only 80% of that of the general population.
Discussion
The data reported in this study bear a certain resemblance to observations in clinical trials that have suggested that some subjects being treated with drugs for hypertension may actually be at increased risk of sudden death. 7 ' 8 However, the data reported here are derived from an observational study and not from a controlled clinical trial with random assignment to treatment. Although an attempt was made to eliminate 12.0 25.9 *High-risk subjects = >20 cigarettes/day, definite high blood pressure, glucose intolerance, cholesterol >240 mg/dl. tECG abormal. Also includes ECG-myocardial infarction as well as left ventricular hypertrophy, intraventricular block, nonspecific abnormality. HBP = high blood pressure; CHD = coronary heart disease; ECG = electrocardiogram. *p<0.01; §p<0.05; Up<0.12; Up<0.07. selection bias, there is no guarantee that some hidden bias has not been overlooked. It is also possible that findings from a clinical trial in which the subjects were deliberately selected to exclude interfering variables such as diabetes or serious illness and in which a precise protocol was followed and compliance and side effects carefully monitored cannot be generalized to all patients with hypertension. As indicated by experience in the referred care groups in both the Multiple Risk Factor Intervention Trial and the Hypertension Detection and Follow-up Program, clinical practice often necessitates treatment under very different circumstances.
Controlled trials indicate that in general, hypertensive persons who receive treatment live longer than those who do not.
2 " 5 However, clinical trials indicate that the benefits of antihypertensive therapy apply mainly to occurrence of stroke, cardiac failure, renal insufficiency, and aortic aneurysm. 23 Data indicating benefits for CHD have been less consistent.
7 ' 8 Trial data on the effects of treatment on sudden death incidence in particular are sparse, indeed.
The Multiple Risk Factor Intervention Trial showed an unfavorable mortality experience in hypertensive men with ECG abnormalities at rest. When compared with those in the usual care group, an adjusted relative risk indicating a 67% excess mortality was noted.
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The excess coronary mortality among the hypertensive men with ECG abnormalities was attributed chiefly to sudden death. Also, this excess mortality was independent of the baseline blood pressure level. An interaction between ECG abnormality and diuretic treatment was noted. The Framingham Study data do not allow an accurate appraisal of the type, amount, and compliance with treatment. However, during the period when most of the sudden deaths occurred, the predominant drug treatments available were diuretics and reserpine.
Studies have shown an association of diuretic therapy with ventricular arrhythmias 13 ' l6 and with sudden death in persons with prior CHD. 17 It is not clear whether hypokalemia is responsible for these associations. 17 Diuretics adversely affect blood lipids 2 " 4 but so do other antihypertensive agents. There is evidence to suggest that hypokalemia may contribute to the occurrence of sudden death, especially in the presence of an increase in circulating epinephrine that accompanies a myocardial infarction, and also in persons with hypoglycemia. 13 The efficacy of antihypertensive drug therapy has been well demonstrated in some clinical trials, 2 ' 3i 5 but the benefits for CHD mortality have not been conclusively demonstrated. 2 " 5 A controlled trial involving a modest sample of older men has also suggested an adverse effect of antihypertensive treatment with diuretics on coronary mortality. 18 The remarkable decline in stroke and cardiovascular mortality in the USA and some other countries over the past 2 decades is to an extent very likely a product of the successful detection and treatment of hypertension." Although the decline in stroke mortality preceded the widespread introduction of effective drug therapy, it definitely has accelerated in its rate of decrease since the emphasis on therapy. This indicates that hypertension control is on the whole beneficial.
However, more detailed information is required to define better the indications, contraindications, best drugs, hazards, and side effects of antihypertensive treatment for the avoidance of coronary heart disease. Therapy for mild to moderate hypertension could well be nonpharmacological for the coronary candidate. There is growing evidence that nonpharmacological therapy may be a reasonable alternative to drug therapy. Such therapy includes weight reduction, reduced sodium intake, increased potassium, magnesium, and calcium, reduced fat, and reduced alcohol intake. 20 However, such measures are at present difficult to implement effectively except in research settings.
As the incidence and mortality from stroke, cardiac failure, and renal failure decline, more emphasis will have to be placed on reducing coronary mortality and sudden death. Antihypertensive agents for this purpose may have to be tailored to a profile that is more effective against atherogenesis and less inclined to increase myocardial irritability. Diuretic therapy tends to worsen the lipid profile and decrease glucose tolerance and serum potassium.
The general efficacy of lowering blood pressure seems well established. We now need better information on the efficacy of various drugs and on nonpharmacological therapy for reducing CHD morbidity and mortality and better data on the proper indications and contraindications for this sequela of hypertension. 
